Apollomics Inc.

APLM ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2024 FY2023 FY2022 FY2021 FY2020
Revenue $0 $0 $0 $0 $0
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development
SG&A Expense
Operating Income $-53.6M $-172.6M $976.0K $-94.8M $-74.9M
Operating Margin
Interest Expense
Pretax Income $-53.6M $-172.6M $-240.8M $-94.8M $-74.9M
Income Tax Expense $259.0K $10.0K $1.0K $1.0K $-85.0K
Net Income $-53.9M $-172.6M $-240.8M $-94.8M $-74.8M
Net Margin
EPS (Basic) $-52.80 $-231.99 $-844.95 $-3.37 $-0.21
EPS (Diluted) $-52.80 $-231.99 $-844.95 $-3.37 $-0.21
Shares Outstanding (Basic) 89.5M
Shares Outstanding (Diluted) 89.5M
Dividends Per Share